TABLE 1.
Demographic and clinical characteristics
| Characteristic | Overall group (n = 4390) | Label‐consistent group (n = 2890) |
|---|---|---|
| Male | 2412 (54.9) | 1587 (54.9) |
| Age (years), median (range) | 54.0 (12.0–88.0) | 54.0 (12.0–88.0) |
| HCV genotype | ||
| 1 | 2096 (47.7) | 1513(52.4) |
| 2 | 962 (21.9) | 651 (22.5) |
| 3 | 884 (20.1) | 485 (16.8) |
| 4/5/6 | 230 (5.2)/56 (1.3)/162 (3.7) | 103 (3.6)/24 (0.8)/114 (3.9) |
| Baseline HCV RNA (IU/ml) | ||
| <1,000,000 | 1628 (37.1) | 1007 (34.8) |
| ≥1,000,000 | 2762 (62.9) | 1883 (65.2) |
| Prior HCV treatment history | ||
| Treatment‐naïve | 3464 (78.9) | 2266 (78.4) |
| Treatment‐experienced | 926 (21.1) | 624 (21.6) |
| DAA compliance a | 4026 (91.7) | 2652 (91.8) |
| Cirrhosis | 907 (20.7) | 515 (17.8) |
| Injection drug use | ||
| Yes, unknown | 285 (6.5) | 189 (6.5) |
| Yes, ≤12 months | 62 (1.4) | 35 (1.2) |
| Yes, >12 months | 941 (21.4) | 564 (19.5) |
| No | 3102 (70.7) | 2102 (72.7) |
| G/P regimen | ||
| 8 weeks | 2582 (58.8) | 2582 (89.3) |
| 12 weeks | 1718 (39.1) | 218 (7.5) |
| 16 weeks | 90 (2.1) | 90 (3.1) |
All results are n (%) unless otherwise stated; percentages are calculated from non‐missing values.
Abbreviations: DAA, direct‐acting antiviral; G/P, glecaprevir/pibrentasvir; HCV, hepatitis C virus; RNA, ribonucleic acid.
a
Compliance was calculated as the percentage of tablets taken relative to the total number of tablets expected to be taken. Compliance was defined as a calculated percentage between 80% and 120%.